HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP)

HeartBeam said its Heart Attack Assessment Technology was accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP). The acceptance is a regulatory-development milestone, not an FDA approval; the headline provides no additional figures or details.